Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.73 |
| ▸ | MAPT | P10636 | 8/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.73 |
| ▸ | RXRA | P19793 | 5/20 | 0.73 |
| ▸ | RARA | P10276 | 4/20 | 0.73 |
| ▸ | RARB | P10826 | 4/20 | 0.73 |
| ▸ | RARG | P13631 | 4/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.73 |
| ▸ | APP | P05067 | 4/20 | 0.73 |
| ▸ | SNCA | P37840 | 4/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.73 |
| ▸ | BLM | P54132 | 3/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | RXRB | P28702 | 2/20 | 0.73 |
| ▸ | RXRG | P48443 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362317 | 0.96 | ALDH1A1 (0.80) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Glycolic Acid SCHEMBL6353225 | 0.94 | ALDH1A1 (0.74) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL4862741 | 0.93 | ALDH1A1 (0.77) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL58183 | 0.93 | ALDH1A1 (0.72) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL11407893 | 0.92 | ALDH1A1 (0.71) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL3427341 | 0.92 | ALDH1A1 (0.71) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL7523937 | 0.91 | ALDH1A1 (0.77) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL7890783 | 0.91 | ALDH1A1 (0.77) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL11125160 | 0.91 | ALDH1A1 (0.77) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL5225545 | 0.91 | ALDH1A1 (0.77) | ALDH1A1MAPTCYP3A4RXRARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065338-B2 | Polysaccharide therapeutic conjugates | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| EP-2397131-B1 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS | UNIV WASHINGTON (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190216937-A1 | POLYSACCHARIDE THERAPEUTIC CONJUGATES | CASE WESTERN RESERVE UNIVERSITY | 2019-07-18 | — | — | US | disclosed |
| US-20190167626-A1 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS | UNIVERSITY OF WASHINGTON | 2019-06-06 | — | — | US | disclosed |
| US-20190133986-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | UNIVERSITY OF WASHINGTON | 2019-05-09 | — | — | US | disclosed |
| US-10226536-B2 | Polysaccharide therapeutic conjugates | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190029986-A1 | THERAPEUTIC REGIMEN AND METHODS FOR TREATING OR AMELIORATING VISUAL DISORDERS ASSOCIATED WITH AN ENDOGENOUS RETINOID DEFICIENCY | RETINAGENIX HOLDINGS LLC | 2019-01-31 | — | — | US | disclosed |
| US-10117845-B2 | Retinal derivatives and methods for the use thereof for the treatment of visual disorders | UNIVERSITY OF WASHINGTON (US) | 2018-11-06 | — | — | US | disclosed |
| US-9987245-B2 | Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency | NOVELION THERAPEUTICS INC. (CA) | 2018-06-05 | — | — | US | disclosed |
| US-20180098955-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | UNIVERSITY OF WASHINGTON | 2018-04-12 | — | — | US | disclosed |
| WO-2011132084-A2 | THERAPEUTIC REGIMEN AND METHOD FOR TREATING OR AMELIORATING VISUAL DISORDERS ASSOCIATED WITH AN ENDOGENOUS RETINOID DEFICIENCY | QLT INC. (CA) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257266-A1 | Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated | QLT, INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-7951841-B2 | 9-Cis- or 11-cis-retinyl succinate, citrate, ketoglutarate, fumarate, malate or oxaloacetate; administering to vertebrate having an endogenous retinoid deficiency; vision defects; 9-cis-retinyl acetate or 9-cis-retinyl succinate; photoreceptor stabilizers; macular degeneration | UNIVERSITY OF WASHINGTON (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2252276-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | University of Washington (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100035986-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | UNIVERSITY OF WASHINGTON (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009102418-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | UNIVERSITY OF WASHINGTON (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-1765322-A4 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS | UNIV WASHINGTON (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20080221208-A1 | Retinal Derivatives and Methods for the Use Thereof for the Treatment of Visual Disorders | UNIVERSITY OF WASHINGTON (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1765322-A2 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS | University of Washington (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002097-A2 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190133986-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | ALDH1A2, ALDH1A3, RBP4 | ALDH1A1 305/4885MAPT 3469/4885CYP3A4 4185/4885 |
| US-10226536-B2 | Polysaccharide therapeutic conjugates | RARG, SI, LRAT | ALDH1A1 1523/4885MAPT 2085/4885CYP3A4 3251/4885 |
| US-20190216937-A1 | POLYSACCHARIDE THERAPEUTIC CONJUGATES | RARG, SI, LRAT | ALDH1A1 1523/4885MAPT 2085/4885CYP3A4 3251/4885 |
| US-20080221208-A1 | Retinal Derivatives and Methods for the Use Thereof for the Treatment of Visual Disorders | NR2E3, ALDH1A2, RARB | ALDH1A1 655/4885MAPT 3190/4885CYP3A4 3536/4885 |
| US-20100035986-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | ALDH1A2, ALDH1A3, RBP4 | ALDH1A1 305/4885MAPT 3469/4885CYP3A4 4185/4885 |
| US-10117845-B2 | Retinal derivatives and methods for the use thereof for the treatment of visual disorders | NR2E3, ALDH1A2, RARB | ALDH1A1 655/4885MAPT 3190/4885CYP3A4 3536/4885 |
| US-20110257266-A1 | Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated | RBP4, RBP1, ALDH1A2 | ALDH1A1 938/4885MAPT 3013/4885CYP3A4 4616/4885 |
| US-20190029986-A1 | THERAPEUTIC REGIMEN AND METHODS FOR TREATING OR AMELIORATING VISUAL DISORDERS ASSOCIATED WITH AN ENDOGENOUS RETINOID DEFICIENCY | RBP4, RBP1, RARB | ALDH1A1 745/4885MAPT 3568/4885CYP3A4 4561/4885 |
| US-20190167626-A1 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS | NR2E3, ALDH1A2, RARB | ALDH1A1 655/4885MAPT 3190/4885CYP3A4 3536/4885 |
| US-11065338-B2 | Polysaccharide therapeutic conjugates | RARG, SI, LRAT | ALDH1A1 1523/4885MAPT 2085/4885CYP3A4 3251/4885 |
| US-20180098955-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | ALDH1A2, ALDH1A3, RBP4 | ALDH1A1 305/4885MAPT 3469/4885CYP3A4 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.